LeMaitre Vascular (LMAT) has been drawing attention after a recent pullback, with the stock flat over the past day but down over the past week, month, and past 3 months. Investors are reassessing what the current pricing implies.

Recent trading has cooled, with the 30 day share price return down 5.02% and the 90 day share price return down 14.55%. However, the year to date share price return of 15.18% and 1 year total shareholder return of 14.53% still point to longer term momentum that investors are weighing against current risks and expectations.

If you are comparing LMAT with other healthcare focused opportunities, it could be a good time to broaden your watchlist with 40 healthcare AI stocks

So with LMAT pulling back over the past quarter yet still showing positive multi-year shareholder returns and trading at a discount to the current analyst price target, is this a fresh buying opportunity, or is the market already pricing in future growth?

Price-to-Earnings of 33.8x: Is it justified?

LeMaitre Vascular currently trades on a P/E of 33.8x, which analysts regard as expensive compared with both its own fair P/E estimate and parts of its peer group.

The P/E ratio links the share price to the company’s earnings per share, so a higher multiple typically reflects higher expectations for future profit growth or perceived quality. For a profitable medical equipment company like LMAT, this is a common yardstick investors use to judge how much they are paying for each dollar of earnings.

On one hand, the stock looks expensive relative to an estimated fair P/E of 20.1x. This level suggests the valuation could move closer to that benchmark if sentiment or assumptions change. On the other hand, LMAT trades at a discount to the peer average P/E of 49.8x. This indicates the market is pricing the company below some comparable medical equipment stocks even with its premium to the fair ratio.

Result: Price-to-Earnings of 33.8x (OVERVALUED)

However, you still need to factor in risks such as a valuation reset if growth expectations cool, as well as competitive pressure across vascular devices that could squeeze future profitability assumptions.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Our DCF Model Says LMAT Looks Expensive

The SWS DCF model points in the opposite direction to the P/E story. With the stock at $92.34 and the model indicating a future cash flow value of $67.96, LMAT screens as overvalued on this framework, which raises questions about how much optimism is already in the price.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out LeMaitre Vascular for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment looking mixed, with both risks and rewards in play, it makes sense to move quickly, review the underlying data yourself, and weigh both sides using the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If LMAT is already on your radar, it makes sense to line up a few more candidates so you are not relying on a single stock story.

• Spot potential bargains hiding in plain sight with the 46 high quality undervalued stocks.
• Focus on stability first by scanning the 67 resilient stocks with low risk scores.
• Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.